Biomarin's Trading Volume Surges 49.35% to 1.77 Billion, Ranks 492nd in Market

On May 20, 2025, Biomarin's trading volume reached 1.77 billion, marking a 49.35% increase from the previous day, ranking 492nd in the day's stock market. Biomarin Pharmaceuticals (BMRN) rose by 0.88%, marking three consecutive days of gains, with a total increase of 2.85% over the past three days.

Biomarin Pharmaceuticals has recently announced that the U.S. Food and Drug Administration (FDA) has approved its new drug, Voxzogo, for the treatment of achondroplasia, a rare genetic disorder that affects bone growth. This approval is a significant milestone for the company, as it expands its portfolio of treatments for rare diseases.

In addition to the FDA approval, Biomarin has also reported positive results from its Phase 3 clinical trial for its gene therapy, BMN 270, for the treatment of hemophilia A. The trial met its primary endpoint, demonstrating a significant reduction in bleeding episodes in patients treated with the therapy. This success further solidifies Biomarin's position as a leader in the development of innovative treatments for rare and genetic diseases.

Furthermore, Biomarin has announced a strategic partnership with a leading biotechnology company to co-develop a new class of therapies for rare diseases. This collaboration is expected to accelerate the development of new treatments and expand Biomarin's pipeline of innovative therapies. The partnership is a testament to Biomarin's commitment to advancing the field of rare disease treatment and improving the lives of patients worldwide.